What is Zacks Research’s Estimate for IOVA FY2026 Earnings?

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Investment analysts at Zacks Research upped their FY2026 earnings per share estimates for Iovance Biotherapeutics in a note issued to investors on Wednesday, September 30th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of ($0.55) for the year, up from their prior forecast of ($0.56). The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($0.45) per share. Zacks Research also issued estimates for Iovance Biotherapeutics’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.09) EPS, Q3 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.09) EPS, FY2027 earnings at ($0.39) EPS, Q1 2028 earnings at ($0.06) EPS, Q2 2028 earnings at ($0.01) EPS, Q3 2028 earnings at $0.00 EPS and FY2028 earnings at ($0.03) EPS.

Other research analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Iovance Biotherapeutics in a research note on Tuesday. Citizens Jmp increased their target price on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the stock a “market outperform” rating in a research report on Friday, August 7th. HC Wainwright increased their target price on Iovance Biotherapeutics from $9.00 to $20.00 and gave the stock a “buy” rating in a report on Tuesday, September 29th. Mizuho lifted their price objective on shares of Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an “outperform” rating in a research note on Tuesday, August 18th. Finally, Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a research report on Friday, August 7th. Nine analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $12.40.

Iovance Biotherapeutics Trading Down 0.1%

NASDAQ:IOVA opened at $14.22 on Friday. The firm has a fifty day simple moving average of $8.35 and a 200 day simple moving average of $5.48. Iovance Biotherapeutics has a 1-year low of $1.76 and a 1-year high of $15.30. The stock has a market capitalization of $6.44 billion, a PE ratio of -19.48 and a beta of 0.76.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. Iovance Biotherapeutics had a negative net margin of 89.11% and a negative return on equity of 40.51%. The business had revenue of $99.31 million for the quarter, compared to analysts’ expectations of $87.83 million. During the same period in the previous year, the firm posted ($0.33) EPS. The firm’s revenue was up 65.7% compared to the same quarter last year.

Hedge Funds Weigh In On Iovance Biotherapeutics

Several institutional investors have recently made changes to their positions in the stock. Rice Hall James & Associates LLC bought a new position in Iovance Biotherapeutics during the second quarter worth about $6,406,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Iovance Biotherapeutics by 100.0% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 818,913 shares of the biotechnology company’s stock valued at $3,407,000 after purchasing an additional 409,449 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Iovance Biotherapeutics during the second quarter worth about $2,726,000. Palo Alto Investors LP purchased a new position in shares of Iovance Biotherapeutics during the second quarter worth about $22,032,229. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Iovance Biotherapeutics in the 2nd quarter worth approximately $449,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

Key Iovance Biotherapeutics News

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Higher revenue outlook supports the bull case. Iovance’s increased FY2026 revenue guidance is the main catalyst behind the recent advance, signaling stronger expectations for product demand and commercial execution. IOVA Stock Hits Over 2-Year Highs – Why Iovance Raised Its FY2026 Revenue Outlook
• Positive Sentiment: Analysts are improving earnings expectations. Zacks Research raised its FY2026 EPS forecast to a loss of $0.55 from $0.56, FY2027 to a loss of $0.39 from $0.44, and FY2028 to a loss of $0.03 from $0.07. Several quarterly estimates were also revised higher, with Q3 2028 projected at breakeven. HC Wainwright likewise raised its estimates, maintained a “Buy” rating, and kept a $20 price target. Analyst earnings estimates for Iovance Biotherapeutics
• Positive Sentiment: Additional analyst support is helping sentiment. Wells Fargo increased its price target, while the broader consensus target was reported as rising 34.74% to $13.06. Zacks’ earnings-surprise methodology also identified IOVA as a stock investors should monitor for a potential earnings beat. Iovance Biotherapeutics Stock Gets Price Target Increase from Wells Fargo
• Neutral Sentiment: Management strengthened its medical leadership. Iovance appointed Noah Berkowitz, M.D., Ph.D., as chief medical officer, adding global drug-development experience in T-cell therapies. The appointment is strategically supportive but is unlikely to materially affect near-term results. Iovance Appoints Noah Berkowitz as Chief Medical Officer
• Negative Sentiment: Losses and valuation risks remain. Iovance is still expected to report a full-year loss, and the reported $13.06 consensus target is below the recent trading level. That gap could limit upside or increase volatility if revenue growth fails to meet elevated expectations.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc is a biotechnology company focused on developing and commercializing individualized cell therapies for patients with cancer. The company’s platform uses tumor-infiltrating lymphocytes (TILs), immune cells collected from a patient’s tumor, expanded in a manufacturing facility and reinfused to help the immune system recognize and attack cancer cells.

Iovance’s lead product, Amtagvi (lifileucel), is an autologous TIL therapy approved by the U.S. Food and Drug Administration for certain adults with unresectable or metastatic melanoma that has progressed following prior treatment with a PD-1-blocking antibody and, when applicable, a BRAF-targeted therapy.